<DOC>
	<DOCNO>NCT01530737</DOCNO>
	<brief_summary>The primary objective study : 1 . To evaluate use Antithrombin ( AT ) concentrate infant less one year age undergoing cardiopulmonary bypass ( CPB ) cardiac surgery The secondary objective study : 1 . To determine administration AT concentrate prior heparinization decrease amount heparin require achieve optimal anticoagulation ( define anti-Xa level ) CPB 2 . To determine decrease activation consumption coagulation protein , platelet subsequent fibrinolysis result improve haemostasis follow CPB 3 . To determine reduction postoperative bleeding associate clinical complication</brief_summary>
	<brief_title>Antithrombin Enhancement May Improve Anticoagulation Efficiency Infants Undergoing Cardiopulmonary Bypass Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>1 . Pediatric patient &lt; 1 year old cardiac defect ( acquire congenital ) require cardiac surgery 2 . Planned cardiac surgery cardiopulmonary bypass 3 . Weight &gt; 2.5kg time surgery 4 . Enrolment CATCH main study ( REB # 1000020203 ) 1 . Preoperative antithrombin activity &gt; 85 % 2 . Prematurity &lt; 36 week gestational age birth 3 . Preoperative use systemic anticoagulant ( i.e . heparin warfarin therapeutic dose ) &gt; 24 hour time within 48 hour prior surgery 4 . Any form coagulopathy thrombophilic disorder 5 . Renal ( blood creatinine estimate GRF &lt; 60ml/min/1.73m2 ) clinical liver failure 6 . Antithrombin replacement therapy prior surgery 7 . Repeat surgery ( include previous ECMO/VAD support prior surgery ) 8 . Patients refusal provide open consent reuse study data</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>364 Days</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pediatric</keyword>
	<keyword>Antithrombin</keyword>
	<keyword>anticoagulation efficiency</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>